Champions Oncology, Inc.
CSBR
$5.96
$0.111.88%
NASDAQ
| 01/31/2026 | 10/31/2025 | 07/31/2025 | 04/30/2025 | 01/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 57.94M | 58.42M | 56.88M | 56.94M | 58.59M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 57.94M | 58.42M | 56.88M | 56.94M | 58.59M |
| Cost of Revenue | 31.36M | 29.15M | 29.31M | 28.39M | 28.37M |
| Gross Profit | 26.58M | 29.28M | 27.57M | 28.56M | 30.22M |
| SG&A Expenses | 19.87M | 18.44M | 17.10M | 16.89M | 16.59M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 60.17M | 55.96M | 53.87M | 52.10M | 51.87M |
| Operating Income | -2.22M | 2.46M | 3.01M | 4.85M | 6.72M |
| Income Before Tax | -2.40M | 2.36M | 2.84M | 4.63M | 6.40M |
| Income Tax Expenses | -55.00K | -74.00K | -81.00K | -74.00K | -26.00K |
| Earnings from Continuing Operations | -2.34 | 2.43 | 2.92 | 4.70 | 6.43 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 61.00K | 61.00K | 30.00K | -- | -- |
| Net Income | -2.28M | 2.49M | 2.95M | 4.70M | 6.43M |
| EBIT | -2.22M | 2.46M | 3.01M | 4.85M | 6.72M |
| EBITDA | -773.00K | 3.97M | 4.56M | 6.49M | 8.43M |
| EPS Basic | -0.17 | 0.18 | 0.22 | 0.34 | 0.47 |
| Normalized Basic EPS | -0.09 | 0.13 | 0.15 | 0.23 | 0.31 |
| EPS Diluted | -0.17 | 0.16 | 0.20 | 0.32 | 0.44 |
| Normalized Diluted EPS | -0.09 | 0.12 | 0.14 | 0.21 | 0.30 |
| Average Basic Shares Outstanding | 55.22M | 55.03M | 54.84M | 54.64M | 54.48M |
| Average Diluted Shares Outstanding | 55.89M | 56.36M | 55.92M | 56.18M | 56.02M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |